Literature DB >> 788740

Preliminary observations on the elimination of acebutolol in severe chronic renal failure.

C M Kaye, J F Dufton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788740      PMCID: PMC1428803          DOI: 10.1111/j.1365-2125.1976.tb00591.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  A study of practolol elimination in all grades of chronic renal failure.

Authors:  C M Kaye; C R Kumana; D A Franklin; L R Baker
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-07

2.  Plasma levels and beta-adrenoceptor blockade with acebutolol, practolol and propranolol in man.

Authors:  M F Cuthbert; R F Collins
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

3.  Differential antianginal responsiveness to acebutolol.

Authors:  P Biron; G Tremblay
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

4.  Cardiac and pulmonary effects of acebutolol.

Authors:  C R Kumana; C M Kaye; M Leighton; P Turner; J Hamer
Journal:  Lancet       Date:  1975-07-19       Impact factor: 79.321

5.  Sectral in the management of angina pectoris.

Authors:  B S Lewis; A Bakst; D J Kitchiner; M S Gotsman
Journal:  S Afr Med J       Date:  1973-08-18

6.  Effectiveness of sectral (M & B 17803A) as a beta-blocking agent in man.

Authors:  B S Lewis; A Bakst; D Kitchiner; M S Gotsman
Journal:  S Afr Med J       Date:  1973-07-14

7.  Properties of acebutolol in twenty patients with cardiac arrhythmias.

Authors:  P Biron; A Proulx; L Lapointe; R Nadeau; G Tremblay
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

  7 in total
  5 in total

Review 1.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

2.  Pharmacokinetics of acebutolol in patients with all grades of renal failure.

Authors:  A Roux; P Aubert; J Guedon; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

3.  Acebutolol metabolite plasma concentration during chronic oral therapy.

Authors:  R A Winkle; P J Meffin; W B Ricks; D C Harrison
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

Review 4.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

5.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.